إعلان
إعلان

DMAC

DMAC logo

DiaMedica Therapeutics Inc. Common Stock

8.16
USD
برعاية
-0.19
-2.29%
٠٩ يناير, ١٥:٥٩ UTC -5
مغلق
exchange

بعد الإغلاق

8.16

0.00
+0.01%

تقارير أرباح DMAC

النسبة الإيجابية المفاجئة

DMAC تفوق 20 من 28 آخر التقديرات.

71%

التقرير التالي

بيانات التقرير القادم
١٦ مارس ٢٠٢٦
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.18
التغير الضمني من Q3 25 (Revenue/ EPS)
--
/
+5.88%
التغير الضمني من Q4 24 (Revenue/ EPS)
--
/
--

DiaMedica Therapeutics Inc. Common Stock earnings per share and revenue

On ١٢ نوفمبر ٢٠٢٥, DMAC reported earnings of -0.17 USD per share (EPS) for Q3 25, missing the estimate of -0.16 USD, resulting in a -4.17% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -14.10% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 المحللين forecast an EPS of -0.18 USD, with revenue projected to reach -- USD, implying an زيادة of 5.88% EPS, and زيادة of 0.00% in Revenue from the last quarter.
الأسئلة الشائعة
For Q3 2025, DiaMedica Therapeutics Inc. Common Stock reported EPS of -$0.17, missing estimates by -4.17%, and revenue of $0.00, 0% as expectations.
The stock price moved down -14.1%, changed from $6.31 before the earnings release to $5.42 the day after.
The next earning report is scheduled for ١٦ مارس ٢٠٢٦.
Based on 6 المحللين, DiaMedica Therapeutics Inc. Common Stock is expected to report EPS of -$0.18 and revenue of -- for Q4 2025.
شيك FXEmpire's Earnings Calendar for today's list of reporting companies.
إعلان